Glecaprevir/pibrentasvir

Drug Profile

Glecaprevir/pibrentasvir

Alternative Names: 2DAA; ABT-493/ABT-530; GLE/PIB; HCV Next Gen; MAVIRET; MAVYRET

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AbbVie; Enanta Pharmaceuticals
  • Developer AbbVie
  • Class Antivirals; Aza compounds; Benzimidazoles; Carbamates; Cyclic ethers; Cyclopentanes; Cyclopropanes; Fluorobenzenes; Piperidines; Pyrrolidines; Quinoxalines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 11 Aug 2017 Launched for Hepatitis C (Treatment-naive, Treatment-experienced) in USA (PO)
  • 07 Aug 2017 AbbVie plans a phase III trial for Hepatitis C (Treatment-naive, Treatment-experienced) in China (NCT03235349)
  • 03 Aug 2017 Registered for Hepatitis C (Treatment-naive, Treatment-experienced) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top